Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: A meta-analysis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lu, Chao ^a   Sang, Jianzhong ^a   He, Haijian ^a   Wan, Xingyong ^a   Lin, Yiming ^a   Li, Lan ^a   Li, Youming ^a   Yu, Chaohui ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PLACEBO; PROBIOTIC AGENT;

ADULT; DIET THERAPY; DIETARY SUPPLEMENT; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; META ANALYSIS; MIDDLE AGED; PATHOGENICITY; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; DIETARY SUPPLEMENTS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; PLACEBOS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84961738606     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23522     Document Type: Article

References (54)

1. Eck, M. et al. MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology 112, 1482-1486 (1997).
2. Peek, R. M., Jr. & Blaser, M. J. Pathophysiology of Helicobacter pylori-induced gastritis and peptic ulcer disease. Am J Med. 102, 200-207 (1997).
3. Huang, J. Q., Sridhar, S., Chen, Y. & Hunt, R. H. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 114, 1169-1179 (1998).
4. Liu, D., He, Q. & Liu, C. Correlations among Helicobacter pylori infection and the expression of cyclooxygenase-2 and vascular endothelial growth factor in gastric mucosa with intestinal metaplasia or dysplasia. J Gastroenterol Hepatol 25, 795-799 (2010).
5. Suerbaum, S. & Michetti, P. Helicobacter pylori infection. N Engl J Med. 347, 1175-1186 (2002).
6. Malfertheiner, P. et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 61, 646-664 (2012).
7. Graham, D. Y. & Fischbach, L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59, 1143-1153 (2010).
8. Liou, J. M. et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut 59, 572-578 (2010).
9. Megraud, F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 64, 1893-1904 (2004).
10. Fuller, R. Probiotics in human medicine. Gut 32, 439-442 (1991).
11. Johnson-Henry, K. C. et al. Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig Dis Sci 49, 1095-1102 (2004).
12. Dang, Y., Reinhardt, J. D., Zhou, X. & Zhang, G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS One 9, e111030 (2014).
13. Szajewska, H., Horvath, A. & Piwowarczyk, A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 32, 1069-1079 (2010).
14. Zhang, M. M., Qian, W., Qin, Y. Y., He, J. & Zhou, Y. H. Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis. World J Gastroenterol 21, 4345-4357 (2015).
15. Kokkotou, E. et al. Serum correlates of the placebo effect in irritable bowel syndrome. Neurogastroenterol Motil 22, 285-e281 (2010).
16. Armuzzi, A. et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 15, 163-169 (2001).
17. Cindoruk, M., Erkan, G., Karakan, T., Dursun, A. & Unal, S. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 12, 309-316 (2007).
18. Cremonini, F. et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 97, 2744-2749 (2002).
19. Manfredi, M. et al. Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy. Helicobacter 17, 254-263 (2012).
20. Myllyluoma, E. et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy-a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther. 21, 1263-1272 (2005).
21. Navarro-Rodriguez, T. et al. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. BMC Gastroenterol 13, 56 (2013).
22. Nista, E. C. et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther. 20, 1181-1188 (2004).
23. Shavakhi, A. et al. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study. Helicobacter 18, 280-284 (2013).
24. Armuzzi, A. et al. Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. Digestion 63, 1-7 (2001).
25. Canducci, F. et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther. 14, 1625-1629 (2000).
26. de, Bortoli, N. et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol 102, 951-956 (2007).
27. Deguchi, R. et al. Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy. J Gastroenterol Hepatol 27, 888-892 (2012).
28. Imase, K. et al. Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota. Microbiol Immunol. 52, 156-161 (2008).
29. Kim, M. N. et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 13, 261-268 (2008).
30. Medeiros, J. A. et al. Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Eur J Clin Microbiol Infect Dis 30, 555-559 (2011).
31. Park, S. K. et al. The effect of probiotics on Helicobacter pylori eradication. Hepatogastroenterology 54, 2032-2036 (2007).
32. Scaccianoce, G. et al. Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci. 12, 251-256 (2008).
33. Sheu, B. S. et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 16, 1669-1675 (2002).
34. Song, M. J. et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter 15, 206-213 (2010).
35. Yasar, B. et al. Efficacy of probiotics in Helicobacter pylori eradication therapy. Turk J Gastroenterol 21, 212-217 (2010).
36. Ziemniak, W. Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics. J Physiol Pharmacol 57 Suppl 3, 123-141 (2006).
37. Lv, Z. et al. Efficacy and safety of probiotics as adjuvant agents for infection: A meta-analysis. Exp Ther Med. 9, 707-716 (2015).
38. Marshall, B. J. & Warren, J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1, 1311-1315 (1984).
39. Walker, M. M. & Talley, N. J. Review article: bacteria and pathogenesis of disease in the upper gastrointestinal tract-beyond the era of Helicobacter pylori. Aliment Pharmacol Ther. 39, 767-779 (2014).
40. Peura, D. Helicobacter pylori: rational management options. Am J Med. 105, 424-430 (1998).
41. Whelan, K. & Myers, C. E. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr. 91, 687-703 (2010).
42. Lee, do K. et al. Probiotic bacteria, B. longum and L. acidophilus inhibit infection by rotavirus in vitro and decrease the duration of diarrhea in pediatric patients. Clin Res Hepatol Gastroenterol 39, 237-244 (2015).
43. Hilton, E., Kolakowski, P., Singer, C. & Smith, M. Efficacy of Lactobacillus GG as a Diarrheal Preventive in Travelers. J Travel Med 4, 41-43 (1997).
44. Friedman, G. The role of probiotics in the prevention and treatment of antibiotic-associated diarrhea and Clostridium difficile colitis. Gastroenterol Clin North Am 41, 763-779 (2012).
45. Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci. USA 105, 16731-16736 (2008).
46. Mack, D. R., Michail, S., Wei, S., McDougall, L. & Hollingsworth, M. A. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 276, G941-950 (1999).
47. Haller, D. et al. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut 47, 79-87 (2000).
48. Singh, V. P., Sharma, J., Babu, S., Rizwanulla. & Singla, A. Role of probiotics in health and disease: a review. J Pak Med Assoc 63, 253-257 (2013).
49. Isolauri, E. et al. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 105, 1643-1650 (1993).
50. Levenstein, S., Rosenstock, S., Jacobsen, R. K. & Jorgensen, T. Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol 13, 498-506 e491 (2015).
51. McDonald, C. J., Mazzuca, S. A. & McCabe, G. P., Jr. How much of the placebo 'effect' is really statistical regression? Stat Med. 2, 417-427 (1983).
52. Hrobjartsson, A. & Gotzsche, P. C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 344, 1594-1602 (2001).
53. Hrobjartsson, A. & Gotzsche, P. C. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med. 256, 91-100 (2004).
54. Jadad, A. R. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17, 1-12 (1996).